Department of Urology, School of Medicine, University of California, San Francisco, CA 94143, USA.
Abstract: Botulinum toxin has recently been approved by the United States FDA for idiopathic and neurogenic detrusor overactivity (overactive bladder). This is an easy clinic procedure that can be performed cystoscopically under local anesthesia with very good success. We will discuss the mechanism of action of this drug, the efficacy, and clinical precautions to ensure a safe and successful result for the patient.
Keywords: OAB; novel therapy; overactive bladder
doi: 10.3978/j.issn.2223-4683.2014.s033
Cite this article as: Deng D. Botox: the novel therapy for OAB. Transl Androl Urol 2014;3(S1):AB33. doi: 10.3978/j.issn.2223-4683.2014.s033
